Acerola for Health & Longevity - Quick Reference Sheet

Acerola for Health & Longevity

Created on 10/19/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Gemini 4 Argon – Audit

Acerola is a tropical fruit and dietary supplement rich in vitamin C and plant pigments, used to maintain vitamin C levels and support skin, immune, and blood-sugar health. Longevity advantages over synthetic oral vitamin C remain unconfirmed, as human studies used blended products or lacked controls. Moderate doses are well tolerated; high doses can cause loose stools, kidney stones in men, or iron overload. (Full Review)

Protocol

Standard longevity regimen
200–500 mg/day L-ascorbic acid
1–3 g/day freeze-dried powder (17–25% vitamin C); men cap at ≤ 400–500 mg/day
Half-life and split dosing
Two 100–250 mg vitamin C doses
Plasma half-life drops to 2–3 hours above the ~70 µmol/L renal threshold
Optimal time of day
Morning and midday meals
Oral doses with meals; avoid intake within 3 hours of exercise
Time to effect
Skin hydration and elasticity gains
8–12 weeks
Improved skin hydration, elasticity, and dermal collagen in 12-week trials
Leukocyte saturation and hepatic enzyme shifts
2–3 weeks
Leukocyte saturation and fasting glucose, urea, ALT, AST, and IgG reductions
Plasma ascorbic acid
1–2 hours
Acute plasma ascorbic acid rise and reduced early urinary excretion

Benefits

Contraindications
  • Individuals with IgE-mediated natural rubber latex allergy or prior acerola hypersensitivity
  • Individuals with hereditary hemochromatosis, thalassemia major (inherited hemoglobin disorder), or sideroblastic anemia (bone-marrow iron-loading anemia)
  • Individuals with calcium oxalate nephrolithiasis, hyperoxaluria, or chronic kidney disease (supplemental doses; theoretical in renal impairment)
  • Individuals with G6PD deficiency or acid-sensitive gastrointestinal disorders (high-dose extracts; theoretical in G6PD deficiency)
Key Interactions
  • Boronic acid proteasome inhibitors (targeted cancer drugs, such as bortezomib) (dosing days; theoretical)
  • Iron chelators (iron-binding drugs, such as deferoxamine) (> 200 mg/day vitamin C)
  • Vitamin K antagonists (anticoagulants, such as warfarin and acenocoumarol) (> 1,000 mg/day)
  • Aluminum-containing over-the-counter antacids (acid neutralizers, such as aluminum hydroxide and magaldrate) (renal impairment; 2–4 hour window)
  • Over-the-counter salicylates and nonsteroidal anti-inflammatory drugs (pain relievers, such as aspirin and ibuprofen) (theoretical)
  • Elemental iron supplements (ferrous sulfate, ferrous bisglycinate) (elevated serum ferritin)
  • Isolated vitamin C and high-oxalate supplements (ascorbic acid, spinach or rhubarb extracts) (≥ 1,000 mg/day in men)
  • Hydrolyzed collagen peptides and polyphenols (grape seed extract, lycopene) (beneficial additive effect)
  • Redox-based laboratory diagnostics (glucose oxidase fingerstick strips, guaiac fecal occult blood tests) (48–72 hours before testing)

Risk & Side Effects

  • High:
  • Medium:
  • Low: Calcium oxalate kidney stones; osmotic diarrhea and gastrointestinal distress; latex-fruit cross-reactive anaphylaxis; rectal seed bezoar and fecal impaction; mild reductions in hemoglobin, leukocyte, and platelet counts
  • Speculative: Dental enamel erosion from acidic pulp and chewables; iron overload aggravation

Monitoring

Marker Target Why
Fasting Plasma Ascorbic Acid ≥ 50–70 µmol/L Confirms systemic vitamin C repletion and tissue saturation
24-Hour Urinary Oxalate < 40 mg/24 hours Detects hyperoxaluria requiring dose reduction or cessation
Serum Ferritin and Transferrin Saturation Ferritin 30–300 ng/mL (men), 15–150 ng/mL (women); transferrin saturation 20–45% Screens for latent iron overload that contraindicates high-dose ascorbate
Fasting Serum Glucose, Urea, ALT, and AST Glucose 3.9–5.5 mmol/L; urea 2.5–7.1 mmol/L; ALT 0.17–0.68 µkat/L; AST 0.17–0.60 µkat/L Tracks metabolic and hepatic enzyme reductions seen with acerola supplementation
Complete Blood Count (Hemoglobin, Neutrophils, Platelets) Hemoglobin 135–175 g/L (men), 120–155 g/L (women); neutrophils 1.8–7.5 × 10⁹/L; platelets 150–400 × 10⁹/L Monitors for mild reductions in hemoglobin, neutrophils, and platelets at high doses

Cadence: Baseline before starting supplementation, follow-up at 4 weeks and 12 weeks, then every 6 to 12 months during long-term maintenance.

Qualitative Assessment

  • Skin hydration and elasticity: Subjective and photographic improvement in skin smoothness, elasticity, and dryness after 8–12 weeks.
  • Gastrointestinal comfort: Absence of loose stools, cramping, or reflux during daily use.
  • Seasonal respiratory resilience: Fewer and shorter seasonal upper respiratory episodes during winter or training.